Chief Executive Officer & Director, Edwards Lifesciences
Search every verified Bernard Zovighian interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Bernard Zovighian, CEO of Edwards Lifesciences, discussed the company's third quarter 2025 financial results on an earnings call. He stated that based on strong Q3 performance, the company was raising its full-year sales growth guidance to the high end of a previous 9 to 10 percent range and raising its EPS guidance range to between $2.56 and $2.62. Zovighian also said the company was raising its full-year TAVR guidance to 7 to 8 percent from a previous 6 to 7 percent range, attributing the quarter's results to factors including a "halo" effect from recent clinical data and guidelines that made TAVR "at the center of a conversation" for heart teams, as well as a less pronounced summer seasonality than usual. Looking ahead, Zovighian said the company expects a good Q4, though he cautioned against taking the Q3 result as "the new normal" for TAVR. He reiterated that Edwards expects to deliver sustainable topline growth and profitability, with TAVR growth in the mid-to-high single digits for the foreseeable future and overall company growth of 10 percent with leverage on EPS. Zovighian noted that the company's strategy is to "innovate to drive sustainable organic topline sales growth" and that R&D spending as a percentage of sales declined from nearly 19 percent in the prior year's third quarter to 18.1 percent, reflecting discipline in prioritizing R&D investments.
“Based on our strong performance in Q3, we are raising full-year sales growth guidance to the high end of a previous 9 to 10 percent range and are also raising our EPS guidance range to between $2.56 and $2.62.”
“The results confirmed that rate of all cause mortality for TAVR remain low and comparable to the surgical controller. Additionally, Sapien performance and durability indicators were excellent and comparable to SAV.”
“The evolution of policy and guideline changes together with the potential of the new US NCD will provide important catalyst resulting in a multi-year growth opportunity for US dollar outside of the US.”
“We continue to expect our full year 2025 surgical global sales will be in the mid single digit driven by Resilia portfolio adoption across our key markets and growth in heart valve procedures for patients best treated surgically.”
EW - Earnings call Q3 2025.
Edwards Lifesciences Corporation 2025 Investor Conference. Twitter - https://twitter.com/i101in #earningscall #StockMarketNews #conferenceCall If you want us to remove your company's earnings call or any other conference call, please reach out to [email protected].
Edwards Lifesciences Corporation EW Q3 2025 Earnings Call --------- In this video, we'll cover the latest quarterly earnings results, ...
We are excited to announce the launch of AlphaStreet Intelligence, a cutting-edge technology driven global ecosystem that connects companies, investors, analysts, and experts. Crafted as an AI-driven market intelligence platform, it not only facilitates interaction among the eco system participants but also accelerates research and decision-making by surfacing self-learning AI insights. The unrivaled intelligence is due to unique combination of platform interactions and syndicated content. I believe that AlphaStreet Intelligence will transform the way market intelligence is approached, make th…
Structural heart innovation is rewriting the future of cardiovascular care—delivering faster recoveries, better outcomes, and a new ...
07/24/2025 Q&A: 26:37 Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical v…
This keynote took place at LSI USA '24 Emerging Medtech Summit in Dana Point, California. This keynote, moderated by Paul ...
Sign in to search the full transcript archive, filter by topic, and access every quote from Bernard Zovighian.